Efficacy
Nobivac® Lyme has been shown to produce borreliacidal antibodies that are highly effective in killing Borrelia burgdorferi.1
In a tick challenge study:
- 30 8-week old puppies were randomly assigned to two groups
- 15 vaccinates and 15 controls received either Nobivac® Lyme or a placebo injection administered subcutaneously on Days 0 and 21
- All dogs were challenged with live B. burgdorferi–infected ticks 3 weeks after the second dose
- Ticks fed for 7 days, then were examined for B. burgdorferi
- Evaluations in dogs included skin biopsies, joint tissue analyses, and assessment for clinical signs of disease
Nobivac® Lyme has also been shown to help prevent Lyme disease–associated joint abnormalities.1
Nobivac® Lyme helps prevent subclinical and clinical signs of illness due to Lyme disease.1
In dogs vaccinated with Nobivac® Lyme…
- No B. burgdorferi were recovered from joint tissues
- No inflammatory changes were seen in joint capsules
- No limb or joint disorders attributable to B. burgdorferi occurred
- No serologic evidence of exposure to B. burgdorferi was present
In control dogs…
- 14 out of 15 had antibodies specific for B. burgdorferi
- 10 out of 15 developed joint stiffness or lameness, or chronic joint inflammation (synovitis)
- 8 out of 15 had isolation of B. burgdorferi from the joint
Reference:1. LaFleur RL, Dant JC, Wasmoen TL, et al. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. Clin Vaccine Immunol. 2009;16(2):253–259.
